Targeting uric acid levels in treating gout

J Ton, MR Kolber - Canadian Family Physician, 2020 - cfp.ca
Best evidence finds that increasing the dosage of allopurinol to achieve a serum urate target
(eg,< 360 μmol/L) does not reduce gout flares, pain, or function compared with standard …

Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy

MP Keith, WR Gilliland - Clinical Pharmacology & Therapeutics, 2011 - Wiley Online Library
Urate‐lowering therapy (ULT), adjusted to achieve and maintain a serum uric acid (SUA) of<
6 mg/dl, remains the standard of care for the chronic management of gout. New urate …

Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews

AS Kydd, R Seth, R Buchbinder, L Falzon… - The Journal of …, 2014 - jrheum.org
Objective. To systematically review the evidence on the efficacy, safety, and cost-
effectiveness of urate-lowering therapy for gout: xanthine oxidase inhibitors (allopurinol and …

Up-titration of allopurinol in patients with gout

CG Jennings, IS Mackenzie, R Flynn, I Ford… - Seminars in arthritis and …, 2014 - Elsevier
Abstract Objectives European League against Rheumatism (EULAR) gout management
guidelines recommend achieving a target urate level< 6.0 mg/dL (< 357 µmol/L). Allopurinol …

Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials

M Fan, J Liu, B Zhao, X Wu, X Li, J Gu… - Clinical …, 2021 - Springer
Objectives To assess the efficacy and safety of the commonly used urate-lowering therapies
(ULTs): febuxostat, allopurinol, and lesinurad in hyperuricemic patients with gout. Methods …

[PDF][PDF] Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol

M Cutolo, MA Cimmino… - Eur Rev Med Pharmacol …, 2017 - europeanreview.org
OBJECTIVE: Hyperuricemia leading to urate crystal formation in tissues represents the
pathophysiological mechanism of gout. Guidelines recommend a therapeutic target of serum …

[HTML][HTML] Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis

C Borghi, F Perez-Ruiz - Eur Rev Med Pharmacol Sci, 2016 - europeanreview.org
OBJECTIVE: In patients with gout, serum uric acid (sUA) concentrations should be lowered
at least below the target of 6 mg/dL (even below 5 mg/dL in patients with severe gout). To …

Design and rationale for the veterans affairs “cooperative study program 594 comparative effectiveness in gout: allopurinol vs. febuxostat” trial

S Timilsina, K Brittan, JR O'Dell, M Brophy… - Contemporary Clinical …, 2018 - Elsevier
Background Gout patients do not routinely achieve optimal outcomes related in part to
suboptimal administration of urate lowering therapy (ULT) including first-line xanthine …

'Treat-to-target'with allopurinol is feasible in patients with gout

S Nanda - Nature Reviews Rheumatology, 2011 - nature.com
50–100 mg per month until adverse events occurred or target serum urate levels (< 360
μmol/l) were reached. of 35 patients, 31 who completed the study had achieved this target …

[PDF][PDF] Current management of gout: practical messages from 2016 EULAR guidelines

G Nuki, M Doherty, P Richette - Pol Arch Intern Med, 2017 - pdfs.semanticscholar.org
ABSTRACT The European League Against Rheumatism published updated
recommendations for the management of gout in 2016, comprising 3 overarching principles …